Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS

Posted by Stanley Muller on Aug 19th, 2026

Handelsbanken Fonder AB purchased a new stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 39,000 shares of the company’s stock, valued at approximately $1,202,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RCUS. GAMMA Investing LLC increased its holdings in shares of Arcus Biosciences by 10.0% in the second quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock worth $122,000 after acquiring an additional 359 shares in the last quarter. Royal Bank of Canada increased its stake in Arcus Biosciences by 14.6% during the 1st quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock worth $102,000 after purchasing an additional 607 shares in the last quarter. Creative Planning raised its holdings in Arcus Biosciences by 2.7% during the 3rd quarter. Creative Planning now owns 29,629 shares of the company’s stock worth $403,000 after buying an additional 771 shares during the period. Hantz Financial Services Inc. lifted its stake in Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after buying an additional 881 shares in the last quarter. Finally, New York State Teachers Retirement System boosted its holdings in shares of Arcus Biosciences by 1.1% in the fourth quarter. New York State Teachers Retirement System now owns 92,431 shares of the company’s stock valued at $2,203,000 after buying an additional 1,000 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on RCUS. Truist Financial began coverage on shares of Arcus Biosciences in a research report on Monday, May 18th. They issued a “buy” rating and a $35.00 price objective on the stock. HC Wainwright increased their price objective on Arcus Biosciences from $32.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Wedbush lifted their target price on Arcus Biosciences from $41.00 to $43.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Morgan Stanley set a $23.00 target price on Arcus Biosciences in a research note on Monday, August 10th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $42.00 price target on shares of Arcus Biosciences in a research note on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.80.

Read Our Latest Report on Arcus Biosciences

Insider Activity

In other Arcus Biosciences news, CAO Alexander Azoy sold 2,562 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $25.77, for a total transaction of $66,022.74. Following the completion of the sale, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,020,002.37. This trade represents a 6.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Juan C. Jaen sold 48,502 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $30.05, for a total value of $1,457,485.10. Following the sale, the president owned 842,307 shares of the company’s stock, valued at approximately $25,311,325.35. This represents a 5.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 102,562 shares of company stock worth $2,975,354. Insiders own 7.60% of the company’s stock.

Arcus Biosciences Price Performance

NYSE:RCUS opened at $29.51 on Wednesday. Arcus Biosciences, Inc. has a 12-month low of $9.81 and a 12-month high of $31.74. The stock’s 50 day moving average price is $28.09 and its two-hundred day moving average price is $24.60. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $3.76 billion, a price-to-earnings ratio of -7.57 and a beta of 0.80.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.17. The firm had revenue of $41.00 million during the quarter, compared to analysts’ expectations of $21.98 million. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The firm’s revenue for the quarter was down 74.4% on a year-over-year basis. On average, analysts anticipate that Arcus Biosciences, Inc. will post -3.51 earnings per share for the current year.

About Arcus Biosciences

(Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.